Research article
Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study
-
* Corresponding author: Karin Broberg karin.broberg@med.lu.se
- † Equal contributors
1 Department of Occupational and Environmental Medicine, Lund University, Lund, Sweden
2 Competence Centre for Clinical Research, Lund University Hospital, Lund, Sweden
3 Department of Surgery, Lund University, Lund, Sweden
4 Department of Oncology, Lund University, Lund, Sweden
5 Department of Clinical Genetics/SCIBLU Genomics, DNA Microarray Resource Centre Lund University, Lund, Sweden
BMC Cancer 2009, 9:140 doi:10.1186/1471-2407-9-140
Published: 11 May 2009Additional files
Additional file 1:
Supplementary tables I–III. Table I. Influence of all polymorphisms studied in RMI1, TOP3A, and BLM on risk for AML/MDS (acute myeloid leukemia/myelodysplastic syndromes). Table II. Influence of all polymorphisms studied RMI1, TOP3A, and BLM on risk for malignant melanoma. Table III. Influence of all polymorphisms studied in RMI1, TOP3A, and BLM on risk for bladder cancer.
Format: DOC Size: 470KB Download file
This file can be viewed with: Microsoft Word Viewer
